

Magnetics, Inc. in carrying out Current Good Manufacturing Practices (cGMPs) as required by the Food and Drug Administration.

AMENDMENTS

In the Specification:

Please delete the phrase "at doses in vast excess, for example, 100 mg/kg body weight" on page 1, lines 25-26, in the Background section.

Please insert the following text into page 3, line 4, after the sentence that ends with "carboxylation." and before the sentence that starts with "Further according to....":

"The term "derivatizing" and related terms (e.g. derivatives, derivatized, derivatization, etc) refer to the conventional sense of functionalization at the reactive sites of the composition."

In the Claims:

Please amend claims 35-36, 45, 57, and 59 as follows:

35. (twice amended) An improved method of administering to a mammalian subject a polysaccharide of the type wherein there is a risk of edematous response, wherein the improvement comprises utilizing for administration a derivatized reduced polysaccharide composition, and in derivatizing the polysaccharide, providing an extent of derivatization sufficient to produce an edematous response, to the derivatized composition, that is decreased in comparison to that resulting from utilizing a polysaccharide that has not been thus derivatized.

36. (twice amended) An improved method of administering to a mammalian subject a dextran composition of the type wherein there is a risk of edematous response, wherein the improvement comprises utilizing for administration carboxymethylated reduced